Generation Bio

Generation Bio Free Cash Flow

Delisted

The Free Cash Flow (FCF) of Generation Bio (GBIO) as of Nov 10, 2026 is -90.96 M USD. In the previous year, Free Cash Flow (FCF) was -60.14 M USD — a change of 51.25% (lower).

Free Cash Flow

-90.96 MUSD

YoY

51.25%

Last updated:

Free Cash Flow (FCF) of Generation Bio is 2024 -90.96 M USD. Free Cash Flow (FCF) of Generation Bio was 2023 -60.14 M USD. It decreases by 51.25% lower compared to the previous year.

The Generation Bio Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
-31.14 M USD
Jan 1, 2019
-60.33 M USD
Jan 1, 2020
-75.66 M USD
Jan 1, 2021
-97.78 M USD
Jan 1, 2022
-111.25 M USD
Jan 1, 2023
-60.14 M USD
Jan 1, 2024
-90.96 M USD
The Generation Bio Free Cash Flow history
YEARFree Cash FlowYoY
-90.96 MUSD+51.25%
-60.14 MUSD-45.94%
-111.25 MUSD+13.78%
-97.78 MUSD+29.23%
-75.66 MUSD+25.41%
-60.33 MUSD+93.74%
-31.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

Free Cash Flow (FCF) of Generation Bio is -90.96 M USD in 2024.

Free Cash Flow (FCF) of Generation Bio changed from -60.14 M USD to -90.96 M USD, representing a 51.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Generation Bio

All Key Metrics — Generation Bio